Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03395184 · ClinicalTrials.gov registry record · Phase 2
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 244
- Enrollment target
NCT03395184 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 244 participants.
The verdict
NCT03395184, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 244 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 weeks) dosed once daily and PF-06700841 (60 mg for 12 weeks) dosed once daily during an induction period of 12 weeks, followed by an open label extension period at doses of 50 mg and 30 mg of PF 06651600 and PF 06700841, respectively, for 52 weeks.
Interventions
- DRUG PF-06651600
- DRUG PF-06700841
- DRUG PF-06651600 Placebo
- DRUG Placebo PF-06700841
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2018-02-02 |
| Est. Completion | 2023-10-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03395184
The ClinicalTrials.gov registry entry for NCT03395184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which PF-06651600 is the first listed.
NCT03395184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03395184 about?
NCT03395184 is a clinical study titled "Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease". The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 weeks) dosed once daily and PF-06700841 (60 mg for 12 weeks) dosed once daily during an induction period of 12 weeks, fol...
What is the current status of trial NCT03395184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 244 participants. The study started on 2018-02-02. Estimated completion is 2023-10-19.
What interventions are being tested in trial NCT03395184?
The interventions under investigation include: PF-06651600 (DRUG), PF-06700841 (DRUG), PF-06651600 Placebo (DRUG), Placebo PF-06700841 (DRUG).
Who is sponsoring clinical trial NCT03395184?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.